CN101184839A - 用于呼吸道病毒感染的RNAi治疗 - Google Patents

用于呼吸道病毒感染的RNAi治疗 Download PDF

Info

Publication number
CN101184839A
CN101184839A CNA2006800114415A CN200680011441A CN101184839A CN 101184839 A CN101184839 A CN 101184839A CN A2006800114415 A CNA2006800114415 A CN A2006800114415A CN 200680011441 A CN200680011441 A CN 200680011441A CN 101184839 A CN101184839 A CN 101184839A
Authority
CN
China
Prior art keywords
sirna
virus
nucleic acid
rnai
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2006800114415A
Other languages
English (en)
Chinese (zh)
Inventor
葛青
缪克斯·库玛尔
詹姆士·安东尼·麦克斯威根
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Marina Biotech Inc
Original Assignee
MDRNA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MDRNA Inc filed Critical MDRNA Inc
Publication of CN101184839A publication Critical patent/CN101184839A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CNA2006800114415A 2005-04-08 2006-04-07 用于呼吸道病毒感染的RNAi治疗 Pending CN101184839A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66994205P 2005-04-08 2005-04-08
US60/669,942 2005-04-08

Publications (1)

Publication Number Publication Date
CN101184839A true CN101184839A (zh) 2008-05-21

Family

ID=37087607

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2006800114415A Pending CN101184839A (zh) 2005-04-08 2006-04-07 用于呼吸道病毒感染的RNAi治疗

Country Status (10)

Country Link
US (1) US20100254945A1 (https=)
EP (1) EP1874802A2 (https=)
JP (1) JP2008535496A (https=)
KR (1) KR20070118703A (https=)
CN (1) CN101184839A (https=)
AU (1) AU2006235364A1 (https=)
CA (1) CA2603842A1 (https=)
NO (1) NO20075655L (https=)
NZ (1) NZ563845A (https=)
WO (1) WO2006110688A2 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103966212A (zh) * 2013-02-06 2014-08-06 霍晋 A型流感病毒NP基因有干扰作用的siRNA序列的设计及应用
CN105228648A (zh) * 2011-10-19 2016-01-06 哈里斯疫苗有限公司 快速产生改良的动物疫苗的方法
CN111201330A (zh) * 2017-10-09 2020-05-26 汉诺威医学院 用于人类呼吸道合胞病毒（hrsv）的诊断和疗法
WO2022199690A1 (zh) * 2021-03-26 2022-09-29 圣诺生物医药技术(苏州)有限公司 一种siRNA药物、药物组合物、siRNA-小分子药物偶联物及其应用
CN118800477A (zh) * 2024-07-11 2024-10-18 中国人民解放军军事科学院军事医学研究院 禽源性流感病毒溢出风险评估方法、设备、介质及产品

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006085987A2 (en) 2004-07-09 2006-08-17 University Of Iowa Research Foundation Rna interference in respiratory epitheial cells
WO2007017759A2 (en) * 2005-03-31 2007-02-15 Ronen Kahana Creating poultry and other animals resistant to viral disease
DK2308514T3 (da) 2007-03-23 2013-09-02 To Bbb Holding B V Konjugater til målrettet lægemiddeltransport gennem blod-hjerne barrieren
EP2146575A4 (en) * 2007-04-12 2010-11-24 Alnylam Pharmaceuticals Inc INFLUENZA POLYNUCLEOTIDES, EXPRESSION CONSTRUCTS, COMPOSITIONS AND METHOD FOR THEIR USE
US20100215588A1 (en) * 2007-04-26 2010-08-26 Rami Skaliter Therapeutic delivery of inhibitory nucleic acid molecules to the respiratory system
EP2160191A4 (en) * 2007-05-15 2011-06-29 Johnson & Johnson Res Pty Ltd SUPPRESSION OF VIRUSES INVOLVED IN A DISEASE OR RESPIRATORY INFECTION
MX2009012317A (es) * 2007-05-16 2010-04-01 Mat Malta Advanced Technologie Tratamiento y prevencion de influenza.
CA2687888A1 (en) * 2007-05-31 2008-12-11 Becton, Dickinson And Company Sequences and methods for detecting influenza a and influenza b virus
EP3000885B1 (en) 2009-12-18 2018-07-25 Arrowhead Pharmaceuticals, Inc. Organic compositions to treat hsf1-related diseases
DK2631291T3 (da) 2010-10-22 2019-06-11 Olix Pharmaceuticals Inc Nukleinsyremolekyler, der inducerer rna-interferens, og anvendelser deraf
CN103826657A (zh) * 2011-04-04 2014-05-28 衣阿华大学研究基金会 改进疫苗免疫原性的方法
US9328347B2 (en) 2011-07-18 2016-05-03 Oregon Health & Science University siRNA useful in the treatment of flavivirus infection
CN103930547A (zh) 2011-09-02 2014-07-16 诺华股份有限公司 用于治疗hsf1相关疾病的有机组合物
CN108148838A (zh) 2012-05-22 2018-06-12 奥利克斯医药有限公司 具有细胞内穿透能力的诱导rna干扰的核酸分子及用途
WO2014138792A1 (en) * 2013-03-14 2014-09-18 Commonwealth Scientific And Industrial Research Organisation Double-stranded rna
EP4454637A3 (en) 2015-11-16 2025-01-08 Olix Pharmaceuticals, Inc. Treatment of age-related macular degeneration using rna complexes that target myd88 or tlr3
CA3022877A1 (en) 2016-02-02 2017-08-10 Olix Pharmaceuticals, Inc. Treatment of angiogenesis-associated diseases using rna complexes that target angpt2 and pdgfb
KR102825946B1 (ko) 2016-02-02 2025-06-27 올릭스 주식회사 IL4Rα, TRPA1, 또는 F2RL1을 표적화하는 RNA 복합체를 사용한 아토피 피부염 및 천식의 치료
US12522827B2 (en) 2016-03-02 2026-01-13 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
RS65707B1 (sr) 2016-03-02 2024-08-30 Univ Leland Stanford Junior Pangenotipska sredstva protiv virusa influence i načini upotrebe istih
US11339392B2 (en) 2016-03-02 2022-05-24 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against influenza virus and methods of using the same
WO2021201996A1 (en) * 2020-02-14 2021-10-07 The Board Of Trustees Of The Leland Stanford Junior University Pan-genotypic agents against respiratory viruses and methods of using the same
WO2017178883A2 (en) 2016-04-11 2017-10-19 Olix Pharmaceuticals, Inc. Treatment of idiopathic pulmonary fibrosis using rna complexes that target connective tissue growth factor
KR101916652B1 (ko) 2016-06-29 2018-11-08 올릭스 주식회사 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도
US11591600B2 (en) 2017-02-10 2023-02-28 OliX Pharmaceuticals. Inc. Long double-stranded RNA for RNA interference
CA3096938A1 (en) 2018-04-10 2019-10-17 Ottawa Hospital Research Institute Microrna-based compositions and methods used in disease treatment
US11702709B2 (en) * 2021-02-09 2023-07-18 Pathogendx, Inc. Combinatorial microarray assay for clade variant detection
WO2024026418A1 (en) * 2022-07-28 2024-02-01 New York University Targeting long non-coding rna chromr in interferon-mediated inflammation in humans
EP4527927A1 (en) 2023-09-22 2025-03-26 Medizinische Hochschule Hannover Oligonucleotide-based strategies to combat respiratory viruses

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) * 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5011769A (en) * 1985-12-05 1991-04-30 Meiogenics U.S. Limited Partnership Methods for detecting nucleic acid sequences
US4876187A (en) 1985-12-05 1989-10-24 Meiogenics, Inc. Nucleic acid compositions with scissile linkage useful for detecting nucleic acid sequences
US5403711A (en) * 1987-11-30 1995-04-04 University Of Iowa Research Foundation Nucleic acid hybridization and amplification method for detection of specific sequences in which a complementary labeled nucleic acid probe is cleaved
US5185243A (en) 1988-08-25 1993-02-09 Syntex (U.S.A.) Inc. Method for detection of specific nucleic acid sequences
US5744101A (en) * 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
US5143854A (en) * 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5800992A (en) * 1989-06-07 1998-09-01 Fodor; Stephen P.A. Method of detecting nucleic acids
US5573907A (en) 1990-01-26 1996-11-12 Abbott Laboratories Detecting and amplifying target nucleic acids using exonucleolytic activity
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
WO1995014106A2 (en) 1993-11-17 1995-05-26 Id Biomedical Corporation Cycling probe cleavage detection of nucleic acid sequences
EP0754240B1 (en) 1994-02-07 2003-08-20 Beckman Coulter, Inc. Ligase/polymerase-mediated genetic bit analysis of single nucleotide polymorphisms and its use in genetic analysis
EP0892808B1 (en) 1996-04-12 2008-05-14 PHRI Properties, Inc. Detection probes, kits and assays
US6037130A (en) * 1998-07-28 2000-03-14 The Public Health Institute Of The City Of New York, Inc. Wavelength-shifting probes and primers and their use in assays and kits
US20030087851A1 (en) * 1999-01-20 2003-05-08 Biozak, Inc. Pharmaceutical composition for treating or preventing influenza, and novel oligonucleotide
US6277607B1 (en) * 1999-05-24 2001-08-21 Sanjay Tyagi High specificity primers, amplification methods and kits
EP1081496A1 (en) * 1999-08-31 2001-03-07 Becton, Dickinson and Company Flow-through assay for visually detecting the presence of influenza A and B
AU2003273336A1 (en) * 2002-09-18 2004-04-08 Isis Pharmaceuticals, Inc. Efficient reduction of target rna's by single- and double-stranded oligomeric compounds
US20060160759A1 (en) * 2002-09-28 2006-07-20 Jianzhu Chen Influenza therapeutic
US20040242518A1 (en) * 2002-09-28 2004-12-02 Massachusetts Institute Of Technology Influenza therapeutic
MXPA05003287A (es) * 2002-09-28 2005-07-05 Massachusetts Inst Technology Influenza terapeutica.
US9486070B2 (en) 2012-10-10 2016-11-08 Stirworks Inc. Height-adjustable support surface and system for encouraging human movement and promoting wellness

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105228648A (zh) * 2011-10-19 2016-01-06 哈里斯疫苗有限公司 快速产生改良的动物疫苗的方法
CN103966212A (zh) * 2013-02-06 2014-08-06 霍晋 A型流感病毒NP基因有干扰作用的siRNA序列的设计及应用
CN111201330A (zh) * 2017-10-09 2020-05-26 汉诺威医学院 用于人类呼吸道合胞病毒（hrsv）的诊断和疗法
WO2022199690A1 (zh) * 2021-03-26 2022-09-29 圣诺生物医药技术(苏州)有限公司 一种siRNA药物、药物组合物、siRNA-小分子药物偶联物及其应用
CN118800477A (zh) * 2024-07-11 2024-10-18 中国人民解放军军事科学院军事医学研究院 禽源性流感病毒溢出风险评估方法、设备、介质及产品
CN118800477B (zh) * 2024-07-11 2025-05-02 中国人民解放军军事科学院军事医学研究院 禽源性流感病毒溢出风险评估方法、设备、介质及产品

Also Published As

Publication number Publication date
WO2006110688A3 (en) 2008-01-10
NO20075655L (no) 2007-11-13
WO2006110688A2 (en) 2006-10-19
US20100254945A1 (en) 2010-10-07
CA2603842A1 (en) 2006-10-19
KR20070118703A (ko) 2007-12-17
WO2006110688A9 (en) 2007-03-15
AU2006235364A1 (en) 2006-10-19
EP1874802A2 (en) 2008-01-09
NZ563845A (en) 2010-09-30
JP2008535496A (ja) 2008-09-04

Similar Documents

Publication Publication Date Title
CN101184839A (zh) 用于呼吸道病毒感染的RNAi治疗
US20100144843A1 (en) Rnai therapeutic for respiratory virus infection
ES2539514T3 (es) Métodos y composiciones para expresar ARN viral de sentido negativo en células de canino
US20060160759A1 (en) Influenza therapeutic
CN101103111A (zh) 用于治疗呼吸道病毒感染的组合物及其用途
KR20050084607A (ko) 인플루엔자 치료제
JP2013504311A (ja) インフルエンザウイルスの調製方法
WO2023030246A1 (zh) 一种用于治疗或预防非洲猪瘟的重组prrsv及其药物组合物
CN106132206B (zh) 鸡禽流感的大肠杆菌介导的siRNA沉默
US20090042823A1 (en) Uses of broad spectrum rnai therapeutics against influenza
WO2021259244A1 (zh) 抑制SARS-COV-2病毒复制的shRNA及其应用
CN101880677B (zh) 针对2009新甲型流感病毒多聚酶基因和核蛋白基因的siRNA序列及其应用
JP2008533990A (ja) インフルエンザ治療剤
JP2023532735A (ja) 組み換えエンテロウイルスおよびその使用
Bhattacharya et al. Detailed molecular biochemistry for novel therapeutic design against Nipah and Hendra virus: a systematic review
CN105586344B (zh) 抑制流感病毒相关基因的siRNA及其应用
HK1121182A (en) Rnai therapeutic for respiratory virus infection
JP2013236622A (ja) 細胞培養組成物、インフルエンザウイルスの生産方法、及び、インフルエンザウイルス
Uhl Cellular Conflicts Between RNA Virus and Host Biology
Cressey RNA Synthesis Initiation by the Nonsegmented Negative-Sense RNA Virus Polymerases
WO2026083945A1 (ja) Ｒｓｖ ｎタンパク質 ｒｎａ配列に基づく新規二本鎖ｒｎａ及びその利用
WO2026058828A1 (ja) Ｒｓｖ ｌタンパク質 ｒｎａ配列に基づく新規二本鎖ｒｎａ及びその利用
Pfeffermann Characterization of the role of host factors in the paramyxovirus life cycle
Sarkar In vitro antiviral efficacy of pleconaril and ribavirin on foot and mouth disease virus
JP2009526516A (ja) 呼吸性ウイルス感染を処置するための組成物およびその使用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1121182

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20080521

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1121182

Country of ref document: HK